ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Hagen JW, Swoger JM, Grandinetti LM, 2015. Cutaneous manifestations of Crohn disease. Dermatol Clin 33: 417–431.
-
2.
Català A, Roé E, Dalmau J, Muñoz C, Yelamos O, Puig L, 2015. Anti-tumour necrosis factor-induced visceral and cutaneous leishmaniasis: case report and review of the literature. Dermatology 230: 204–207.
-
3.
Al-Dwibe H, Amro A, Gashout A, El-Zurghany A, El-Zubi S, El-Hashme M, Hamarsheh O, Maree M, 2018. A pyoderma gangrenous-like cutaneous leishmaniasis in a Libyan woman with rheumatoid arthritis: a case report. BMC Res Notes 11: 158.
-
4.
Handler MZ, Patel PA, Kapila R, Al-Qubati Y, Schwartz RA, 2015. Cutaneous and mucocutaneous leishmaniasis: differential diagnosis, diagnosis, histopathology, and management. J Am Acad Dermatol 73: 911–928.
-
5.
van Griensven J, Carrillo E, López-Vélez R, Lynen L, Moreno J, 2014. Leishmaniasis in immunosuppressed individuals. Clin Microbiol Infect 20: 286–299.
-
6.
Borruel N 2017. P683 Leishmania infantum asymptomatic infection in inflammatory bowel disease patients under anti-TNF-α treatment. J Crohn’s Colitis 11: S429.
-
7.
Carrillo E, Carrasco-Antón N, LópezMedrano F, Salto E, Fernández L, San Martín JV, Alvar J, Aguado JM, Moreno J, 2015. Cytokine release assays as tests for exposure to Leishmania, and for confirming cure from leishmaniasis, in solid organ transplant recipients. PLoS Negl Trop Dis 9: e0004179.
-
8.
Marcoval J, Penín RM, Sabé N, Valentí-Medina F, Bonfill-Ortí M, Martínez-Molina L, 2017. Cutaneous leishmaniasis associated with anti-tumour necrosis factor-α drugs: an emerging disease. Clin Exp Dermatol 42: 331–334.
-
9.
Maritati M, Trentini A, Michel G, Bellini T, Almugadam S, Hanau S, Govoni M, Marty P, Contini C, 2018. Subclinical Leishmania infection in patients with rheumatic diseases under biological drugs. Infection 46, 801–809.
-
10.
Guillén MC 2020. Leishmania infantum asymptomatic infection in inflammatory bowel disease patients under anti-TNF therapy. Heliyon 6: e03940.
-
11.
Guedes-Barbosa LS, Pereira da Costa I, Fernandes V, da Mota LMH, de Menezes I, Scheinberg MA, 2013. Leishmaniasis during anti-tumor necrosis factor therapy: report of 4 cases and review of the literature (additional 28 cases). Semin Arthritis Rheum 43: 152–157.
-
12.
Bosch-Nicolau P, Ubals M, Salvador F, Sánchez-Montalvá A, Aparicio G, Erra A, de Salazar PM, Sulleiro E, Molina I, 2019. Leishmaniasis and tumor necrosis factor alpha antagonists in the Mediterranean basin. A switch in clinical expression. PLoS Negl Trop Dis 13: e0007708.
Case Report: Cutaneous Leishmaniasis Misdiagnosed as Pyoderma Gangrenosum
ABSTRACT
With an estimated prevalence of 0.7%, pyoderma gangrenosum (PG) is the most frequent type of reactive skin lesions seen in the setting of inflammatory bowel disease, together with metastatic Crohn’s disease. However, in the case of persistent cutaneous ulcerations in patients with Crohn’s disease under biologic and/or immunosuppressive therapy, infectious or malignant etiologies should be excluded. We report a case of multiple difficult-to-treat skin ulcerations due to Leishmania in a patient with Crohn’s disease treated with antitumor necrosis factor-alpha drugs, misinterpreted for a long time as PG.
Author Notes
Authors’ addresses: Ambra Di Altobrando, Cosimo Misciali, Beatrice Raone, and Valeria Gaspari, Dermatology Unit, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy, E-mails: ambra.dialtobrando@studio.unibo.it, cosimo.misciali@aosp.bo.it, beatrice.raone@libero.it, and gasparivaleria@yahoo.com. Luciano Attard, Infectious Diseases Unit, Department of Medical and Surgical Sciences, St. Orsola Malpighi University Hospital, Bologna, Italy, E-mail: luciano.attard@aosp.bo.it.